{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T19:00:37Z","timestamp":1786474837546,"version":"build-2736575974"},"update-to":[{"DOI":"10.1002\/14651858.cd011640","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,3,30]],"date-time":"2017-03-30T00:00:00Z","timestamp":1490832000000}}],"reference-count":239,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011640.pub2","type":"journal-article","created":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T04:49:22Z","timestamp":1490935762000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD)"],"prefix":"10.1002","volume":"2017","author":[{"given":"Rosa","family":"Lombardi","sequence":"first","affiliation":[{"name":"Royal Free Hospital and the UCL Institute of Liver and Digestive Health; Sheila Sherlock Liver Centre; London UK NW3 2QG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Onali","sequence":"additional","affiliation":[{"name":"Royal Free Hospital and the UCL Institute of Liver and Digestive Health; Sheila Sherlock Liver Centre; London UK NW3 2QG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Thorburn","sequence":"additional","affiliation":[{"name":"Royal Free Hospital and the UCL Institute of Liver and Digestive Health; Sheila Sherlock Liver Centre; London UK NW3 2QG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian R","family":"Davidson","sequence":"additional","affiliation":[{"name":"Royal Free Campus, UCL Medical School; Department of Surgery; Pond Street London UK NW3 2QG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurinchi Selvan","family":"Gurusamy","sequence":"additional","affiliation":[{"name":"Royal Free Campus, UCL Medical School; Department of Surgery; Pond Street London UK NW3 2QG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Tsochatzis","sequence":"additional","affiliation":[{"name":"Royal Free Hospital and the UCL Institute of Liver and Digestive Health; Sheila Sherlock Liver Centre; London UK NW3 2QG"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,3,30]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD011640.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011640.pub2-BIB0002|cit2","first-page":"S116","article-title":"Effect of telmisartan on histological activity and fibrosis of non alcoholic steatohepatitis patient a one year randomized control trial","volume":"9","author":"Alam","year":"2015","journal-title":"Hepatology International"},{"issue":"1","key":"10.1002\/14651858.CD011640.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4103\/1319-3767.173762","article-title":"Effect of telmisartan on histological activity and fibrosis of non-alcoholic steatohepatitis: A 1-year randomized control trial","volume":"22","author":"Alam","year":"2016","journal-title":"Saudi Journal of Gastroenterology"},{"issue":"16","key":"10.1002\/14651858.CD011640.pub2-BIB0004|cit4","first-page":"3118","article-title":"Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study","volume":"19","author":"Aller","year":"2015","journal-title":"European Review for Medical & Pharmacological Sciences"},{"issue":"10019","key":"10.1002\/14651858.CD011640.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (lean): A multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0006|cit6","first-page":"633","article-title":"Effects of metformin plus vitamin E versus metformin alone in treatment of NAFLD: a randomized clinical trial","volume":"28","author":"Askarimoghadam","year":"2013","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD011640.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1185\/030079906X104696","article-title":"Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study","volume":"22","author":"Athyros","year":"2006","journal-title":"Current Medical Research & Opinion"},{"issue":"8","key":"10.1002\/14651858.CD011640.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.metabol.2005.03.010","article-title":"Targeting vascular risk in patients with metabolic syndrome but without diabetes","volume":"54","author":"Athyros","year":"2005","journal-title":"Metabolism: Clinical and Experimental"},{"issue":"10","key":"10.1002\/14651858.CD011640.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"68","DOI":"10.18565\/cardio.2015.10.68-75","article-title":"Safety and efficacy of amlodipine, lisinopril and rosuvastatin therapy in patients with metabolic syndrome and nonalcoholic fatty liver disease","volume":"55","author":"Baranova","year":"2015","journal-title":"Kardiologiya"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0010|cit10","first-page":"S73","article-title":"Curcumin, anti-oxidant, and pioglitazone therapy with inclusion of vitamin E in non-alcoholic fatty liver disease-a randomized double blind placebo controlled trial (captive)","volume":"7","author":"Basu","year":"2013","journal-title":"Hepatology International"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.14309\/00000434-201310001-00505","article-title":"Curcumin, antioxidant, and pioglitazone therapy with inclusion of vitamin E in non-alcoholic fatty liver disease: a randomized, open-label, placebo-controlled clinical prospective trial (captive)","volume":"108","author":"Basu","year":"2013","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"A23","DOI":"10.1136\/gutjnl-2013-304907.052","article-title":"Curcumin, anti-oxidant, and pioglitazone therapy with inclusion of vitamin E in non alcoholic fatty liver disease-a randomized open label placebo controlled clinical prospective trial (captive)","volume":"62","author":"Basu","year":"2013","journal-title":"Gut"},{"issue":"5","key":"10.1002\/14651858.CD011640.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"S1011","DOI":"10.1016\/S0016-5085(13)63754-3","article-title":"Curcumin, anti-oxidant, and pioglitazone therapy with inclusion of vitamin E in non alcoholic fatty liver disease-a randomized open label placebo controlled clinical prospective trial (captive)","volume":"144","author":"Basu","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"A204","DOI":"10.1136\/gutjnl-2012-302514c.50","article-title":"Effect of vitamin E and alfa lipoic acid (ala) in non-alcoholic fatty liver disease: a randomise placebo control open label prospective clinical trial: VAIN trial","volume":"61","author":"Basu","year":"2012","journal-title":"Gut"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0015|cit15","first-page":"208","article-title":"Effect of vitamin E and alfa lipoic acid in non alcoholic fatty liver disease: a randomized clinical trial","volume":"27","author":"Basu","year":"2012","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.14309\/00000434-201110002-00346","article-title":"Effect of vitamin E and alfa lipoic acid (ala) in non alcoholic fatty liver disease: A randomized placebo control open label prospective clinical trial - VAIN trial","volume":"106","author":"Basu","year":"2011","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0017|cit17","first-page":"1145A","article-title":"Effect of vitamin E and alfa lipoic acid (ala) in non alcoholic fatty liver disease: a randomized placebo control open label prospective clinical trial - VAIN trial","volume":"54","author":"Basu","year":"2011","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0018|cit18","first-page":"S63","article-title":"Effect of vitamin E and alpha lipoic acid (ala) in non alcoholic fatty liver disease: a randomized placebo-controlled open-label prospective clinical trial - VAIN trial","volume":"47","author":"Basu","year":"2012","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0019|cit19","doi-asserted-by":"crossref","unstructured":"Basu PP Shah NJ Aloysius MM Jr. RSB Effect of vitamin E and alpha lipoic acid in nonalcoholic fatty liver disease: a randomized, placebo-controlled, open-label, prospective clinical trial (VAIN trial) Open Journal of Gastroenterology 2014 199 207","DOI":"10.4236\/ojgas.2014.45030"},{"issue":"4","key":"10.1002\/14651858.CD011640.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jhep.2007.04.013","article-title":"Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis","volume":"47","author":"Balas","year":"2007","journal-title":"Journal of Hepatology"},{"issue":"22","key":"10.1002\/14651858.CD011640.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0022|cit22","first-page":"15","article-title":"The efficacy of eurosil 85-vit. E complex on metabolic profile in adults with non alcoholic fatty liver disease (NAFLD). A double-blind randomized placebo-controlled clinical study","volume":"45","author":"Bonfrate","year":"2015","journal-title":"European Journal of Clinical Investigation"},{"issue":"5","key":"10.1002\/14651858.CD011640.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1572-0241.2005.41583.x","article-title":"A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease","volume":"100","author":"Bugianesi","year":"2005","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"S269","DOI":"10.1016\/S0168-8278(15)30166-5","article-title":"Silymarin for the treatment of non-alcoholic steatohepatitis: Interim analysis of a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Chan","year":"2015","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"S358","DOI":"10.1016\/S0168-8278(09)60989-2","article-title":"Can disease progression in non-alcoholic steatohepatitis be stopped?","volume":"50","author":"Copaci","year":"2009","journal-title":"Journal of Hepatology"},{"issue":"13","key":"10.1002\/14651858.CD011640.pub2-BIB0026|cit26","first-page":"1326","article-title":"Efficacy of rosiglitazone in treatment of nonalcoholic fatty liver disease and its relations with adiponectin","volume":"14","author":"Cui","year":"2006","journal-title":"World Chinese Journal of Digestology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD011640.pub2-BIB0027|cit27","first-page":"248A","article-title":"Extended treatment with pioglitazone improves liver histology in patients with prediabetes or type 2 diabetes mellitus and NASH","volume":"58","author":"Cusi","year":"2013","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0028|cit28","first-page":"A309","article-title":"Safety and efficacy of long-term pioglitazone treatment for patients with prediabetes or t2dm and NASH","volume":"62","author":"Cusi","year":"2013","journal-title":"Diabetes"},{"issue":"8","key":"10.1002\/14651858.CD011640.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/j.1478-3231.2009.02037.x","article-title":"Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis","volume":"29","author":"Balmer","year":"2009","journal-title":"Liver International"},{"issue":"12","key":"10.1002\/14651858.CD011640.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.cgh.2006.09.025","article-title":"Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis","volume":"4","author":"Dufour","year":"2006","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD011640.pub2-BIB0031|cit31","first-page":"124","article-title":"Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment","volume":"16","author":"Ersoz","year":"2005","journal-title":"Turkish Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD011640.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/MEG.0b013e32834ba188","article-title":"Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis","volume":"24","author":"Fogari","year":"2012","journal-title":"European Journal of Gastroenterology & Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011640.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0168-8278(11)60022-6","article-title":"Losartan alone or combined with simvastatin improved visceral adipose tissue and inflammation in hypertensive normocholesterolemic patients with non-alcoholic hepatic steatosis","volume":"54","author":"Fogari","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD011640.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/ajg.2010.299","article-title":"Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis heart study randomized clinical trial","volume":"106","author":"Foster","year":"2011","journal-title":"American Journal of Gastroenterology"},{"issue":"8","key":"10.1002\/14651858.CD011640.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/ijo.2010.40","article-title":"Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study","volume":"34","author":"Garinis","year":"2010","journal-title":"International Journal of Obesity"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011640.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S0168-8278(09)60057-X","article-title":"Metabolic and anti-inflammatory beneficial effects of pioglitazone (pio) treatment in patients with non-alcoholic steatohepatitis (NASH) and their associations with histological improvement","volume":"50","author":"Gastaldelli","year":"2009","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD011640.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s12072-012-9387-y","article-title":"Impact of combined therapy with alpha-lipoic and ursodeoxycolic acid on nonalcoholic fatty liver disease: double-blind, randomized clinical trial of efficacy and safety","volume":"7","author":"Gianturco","year":"2013","journal-title":"Hepatology International"},{"issue":"10","key":"10.1002\/14651858.CD011640.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1365-2036.2009.04122.x","article-title":"Clinical trial: a nutritional supplement viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease","volume":"30","author":"Gomez","year":"2009","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD011640.pub2-BIB0039|cit39","first-page":"191","article-title":"The efficacy of silymarin in decreasing transaminase activities in non-alcoholic fatty liver disease: a randomized controlled clinical trial","volume":"8","author":"Hajaghamohammadi","year":"2008","journal-title":"Hepatitis Monthly"},{"issue":"8","key":"10.1002\/14651858.CD011640.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"e6099","DOI":"10.5812\/hepatmon.6099","article-title":"Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic fatty liver disease: a randomized controlled pilot study","volume":"12","author":"Hajiaghamohammadi","year":"2012","journal-title":"Hepatitis Monthly"},{"issue":"11","key":"10.1002\/14651858.CD011640.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1111\/j.1572-0241.2003.08699.x","article-title":"Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis","volume":"98","author":"Harrison","year":"2003","journal-title":"American Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD011640.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/hep.22575","article-title":"Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial","volume":"49","author":"Harrison","year":"2009","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"4","key":"10.1002\/14651858.CD011640.pub2-BIB0043|cit43","first-page":"265","article-title":"A placebo-controlled trial of silymarin in patients with nonalcoholic fatty liver disease","volume":"9","author":"Hashemi","year":"2009","journal-title":"Hepatitis Monthly"},{"issue":"7","key":"10.1002\/14651858.CD011640.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/00365520902845268","article-title":"Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial","volume":"44","author":"Haukeland","year":"2009","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD011640.pub2-BIB0045|cit45","first-page":"334A","article-title":"A randomized, placebo controlled trial with metformin in patients with NAFLD","volume":"48","author":"Haukeland","year":"2008","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"3","key":"10.1002\/14651858.CD011640.pub2-BIB0046|cit46","first-page":"221","article-title":"Efficacy of pioglitazone in treatment of 60 patients with nonalcoholic steatohepatitis","volume":"10","author":"Jin","year":"2010","journal-title":"Pharmaceutical Care and Research"},{"issue":"2","key":"10.1002\/14651858.CD011640.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s12072-012-9395-y","article-title":"The influence of pioglitazone on the plasma amino acid profile in patients with nonalcoholic steatohepatitis (NASH)","volume":"7","author":"Kakazu","year":"2013","journal-title":"Hepatology International"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD011640.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"S344","DOI":"10.1016\/S0168-8278(14)60981-8","article-title":"A randomized controlled trial to study the efficacy of combination of pentoxiphylline and vitamin E versus vitamin E in patients with non-alcoholic steatohepatitis","volume":"60","author":"Kedarisetty","year":"2014","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0049|cit49","first-page":"12","article-title":"Comparison of different treatment regimens in patients with nonalcoholic fatty liver disease","volume":"7","author":"Klyarytskaya","year":"2015","journal-title":"Eksperimental'Naia i Klinicheskaia Gastroenterologiia"},{"issue":"2","key":"10.1002\/14651858.CD011640.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1053\/jhep.2003.50316","article-title":"Cytokines and NASH: A pilot study of the effects of lifestyle modification and vitamin E","volume":"38","author":"Kugelmas","year":"2003","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"2","key":"10.1002\/14651858.CD011640.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/hep.23727","article-title":"High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Leuschner","year":"2010","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"9","key":"10.1002\/14651858.CD011640.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.14309\/00000434-200609001-00346","article-title":"Is the lipid reduction seen with high-dose pravastatin (prava) associated with a fall in alt values in hypercholesterolemic pts with NAFLD? Results from a prospective, randomized double-blind, placebo (pbo)-controlled trial","volume":"101","author":"Lewis","year":"2006","journal-title":"American Journal of Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD011640.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/hep.20092","article-title":"Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial","volume":"39","author":"Lindor","year":"2004","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"2","key":"10.1002\/14651858.CD011640.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/1756283X15621232","article-title":"Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the Mozart trial","volume":"9","author":"Lin","year":"2016","journal-title":"Therapeutic Advances in Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD011640.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/hep.27647","article-title":"Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (Mozart trial)","volume":"61","author":"Loomba","year":"2015","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0056|cit56","first-page":"642A","article-title":"Tocotrienols and nonalcoholic fatty liver: a clinical experience","volume":"52","author":"Magosso","year":"2010","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"1","key":"10.1002\/14651858.CD011640.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/1475-2891-12-166","article-title":"Tocotrienols for normalisation of hepatic echogenic response in nonalcoholic fatty liver: a randomised placebo-controlled clinical trial","volume":"12","author":"Magosso","year":"2013","journal-title":"Nutrition Journal"},{"issue":"3","key":"10.1002\/14651858.CD011640.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1665-2681(19)32103-9","article-title":"Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease. A double-blind, placebo-controlled trial","volume":"3","author":"Mendez-Sanchez","year":"2004","journal-title":"Annals of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD011640.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0168-8278(02)00441-5","article-title":"Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study","volume":"38","author":"Merat","year":"2003","journal-title":"Journal of Hepatology"},{"issue":"65","key":"10.1002\/14651858.CD011640.pub2-BIB0060|cit60","first-page":"1338","article-title":"Nateglinide is useful for nonalcoholic steatohepatitis (NASH) patients with type 2 diabetes","volume":"52","author":"Morita","year":"2005","journal-title":"Hepato-Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD011640.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid x receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD011640.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00592-008-0067-2","article-title":"The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"46","author":"Nar","year":"2009","journal-title":"Acta Diabetologica"},{"issue":"10","key":"10.1002\/14651858.CD011640.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/MCG.0b013e31819c392e","article-title":"A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial","volume":"43","author":"Nelson","year":"2009","journal-title":"Journal of Clinical Gastroenterology"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0064|cit64","first-page":"332A","article-title":"Longitudinal changes in fib-4 and improvement in fibrosis stage with obeticholic acid: a secondary analysis of flint trial","volume":"62","author":"Chalasani","year":"2015","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"S271","DOI":"10.1016\/S0168-8278(15)30169-0","article-title":"Separate and combined effects of obeticholic acid and weight loss in nonalcoholic steatohepatitis (NASH)","volume":"62","author":"Hameed","year":"2015","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0066|cit66","first-page":"331A","article-title":"Clinical and metabolic effects associated with weight loss and obeticholic acid in nonalcoholic steatohepatitis (NASH)","volume":"62","author":"Hameed","year":"2015","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"4 Supple 1","key":"10.1002\/14651858.CD011640.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"S1144","DOI":"10.1016\/S0016-5085(16)33861-6","article-title":"Evaluation of effects of concomitant medications for NASH and associated comorbidities on histological improvements with obeticholic acid","volume":"150","author":"Kowdley","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"S487","DOI":"10.1016\/S0168-8278(16)00832-1","article-title":"Evaluation of effects of concomitant medications for non-alcoholic steatohepatitis and associated comorbidities on histological improvements with obeticholic acid","volume":"1","author":"Kowdley","year":"2016","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"S272","DOI":"10.1016\/S0168-8278(15)30172-0","article-title":"Obeticholic acid for NASH: Benefits in a high risk subgroup and the effects of concomitant statin use","volume":"62","author":"Neuschwander-Tetri","year":"2015","journal-title":"Journal of Hepatology"},{"issue":"9972","key":"10.1002\/14651858.CD011640.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid x nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (flint): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD011640.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/MEG.0b013e32832e2baf","article-title":"Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease","volume":"22","author":"Omer","year":"2010","journal-title":"European Journal of Gastroenterology & Hepatology"},{"issue":"7","key":"10.1002\/14651858.CD011640.pub2-BIB0074|cit72","doi-asserted-by":"crossref","first-page":"E105","DOI":"10.1016\/j.cgh.2015.04.118","article-title":"An open label randomized control study to compare the efficacy of vitamin E versus ursodeoxycholic acid in non-diabetic Indian NAFLD patients","volume":"13","author":"Parikh","year":"2015","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD011640.pub2-BIB0072|cit73","doi-asserted-by":"crossref","first-page":"192","DOI":"10.4103\/1319-3767.182451","article-title":"An open-label randomized control study to compare the efficacy of vitamin E versus ursodeoxycholic acid in nondiabetic and noncirrhotic Indian NAFLD patients","volume":"22","author":"Parikh","year":"2016","journal-title":"Saudi Journal of Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011640.pub2-BIB0073|cit74","first-page":"S110","article-title":"An open label randomized control study to compare the efficacy of vitamin E versus ursodeoxycholic acid in non diabetic Indian NAFLD patients","volume":"9","author":"Parikh","year":"2015","journal-title":"Hepatology International"},{"issue":"4","key":"10.1002\/14651858.CD011640.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1177\/1470320311402110","article-title":"Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease","volume":"12","author":"Polyzos","year":"2011","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"12","key":"10.1002\/14651858.CD011640.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/hepr.12244","article-title":"Hepatic molecular effects of rosiglitazone in human non-alcoholic steatohepatitis suggest long-term pro-inflammatory damage","volume":"44","author":"Lemoine","year":"2014","journal-title":"Hepatology Research"},{"issue":"1","key":"10.1002\/14651858.CD011640.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2008.03.078","article-title":"Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial","volume":"135","author":"Ratziu","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0168-8278(09)60049-0","article-title":"A multicentric, double-blind, randomised-controlled trial (RCT) of high dose ursodeoxycholic acid in patients with non-alcoholic steatohepatitis (NASH)","volume":"50","author":"Ratziu","year":"2009","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD011640.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jhep.2010.08.030","article-title":"A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis","volume":"54","author":"Ratziu","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"10","key":"10.1002\/14651858.CD011640.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.cgh.2014.01.040","article-title":"Lack of efficacy of an inhibitor of pde4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis","volume":"12","author":"Ratziu","year":"2014","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD011640.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD011640.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"e9270","DOI":"10.5812\/hepatmon.9270","article-title":"The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic fatty liver disease: a randomized double blinded clinical trial","volume":"13","author":"Razavizade","year":"2013","journal-title":"Hepatitis Monthly"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0083|cit83","first-page":"247","article-title":"Comparison of the therapeutic effects of pioglitazone and metformin in nonalcoholic steatohepatitis","volume":"27","author":"Razavizadeh","year":"2012","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0084|cit84","first-page":"270","article-title":"Comparison of the therapeutic effects of vitamin E and silimarin in nonalcoholic steatohepatitis","volume":"27","author":"Razavizadeh","year":"2012","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"12","key":"10.1002\/14651858.CD011640.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.cgh.2014.04.038","article-title":"The fatty acid-bile acid conjugate aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease","volume":"12","author":"Safadi","year":"2014","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD011640.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1590\/S0100-879X2003000600007","article-title":"A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid","volume":"36","author":"Santos","year":"2003","journal-title":"Brazilian Journal of Medical and Biological Research"},{"issue":"12","key":"10.1002\/14651858.CD011640.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S1542-3565(04)00457-4","article-title":"A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis","volume":"2","author":"Sanyal","year":"2004","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0088|cit88","first-page":"224A","article-title":"Nash resolution is associated with improvements in HDL and triglycerides but not in LDL or non-HDL-C","volume":"60","author":"Corey","year":"2014","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"3","key":"10.1002\/14651858.CD011640.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/MPG.0000000000000584","article-title":"Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease","volume":"60","author":"Corey","year":"2015","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"issue":"1","key":"10.1002\/14651858.CD011640.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.27235","article-title":"Treatment response in the PIVENS trial is associated with decreased hedgehog pathway activity","volume":"61","author":"Guy","year":"2015","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"18","key":"10.1002\/14651858.CD011640.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD011640.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jceh.2012.10.010","article-title":"A randomized controlled trial comparing efficacy of pentoxifylline and pioglitazone on metabolic factors and liver histology in patients with non-alcoholic steatohepatitis","volume":"2","author":"Sharma","year":"2012","journal-title":"Journal of Clinical and Experimental Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD011640.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1756283X09105462","article-title":"The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): A pilot trial","volume":"2","author":"Shields","year":"2009","journal-title":"Therapeutic Advances in Gastroenterology"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"S282","DOI":"10.1016\/S0168-8278(15)30191-4","article-title":"A placebo-controlled, multicenter, double-blind, randomised trial of emricasan in subjects with non-alcoholic fatty liver disease (NAFLD) and raised transaminases","volume":"62","author":"Shiffman","year":"2015","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0095|cit95","first-page":"A661","article-title":"A comparative study of effect of insulin sensitizers and statins in nonalcoholic fatty liver disease (NAFLD)","volume":"64","author":"Siddique","year":"2015","journal-title":"Diabetes"},{"issue":"9","key":"10.1002\/14651858.CD011640.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.metabol.2011.01.011","article-title":"Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial","volume":"60","author":"Sofer","year":"2011","journal-title":"Metabolism: Clinical and Experimental"},{"issue":"1","key":"10.1002\/14651858.CD011640.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s12072-015-9649-6","article-title":"Effect of metformin treatment on circulating osteoprotegerin in patients with nonalcoholic fatty liver disease","volume":"10","author":"Sofer","year":"2016","journal-title":"Hepatology International"},{"issue":"8","key":"10.1002\/14651858.CD011640.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1055\/s-0034-1395652","article-title":"Does metformin treatment influence bone formation in patients with nonalcoholic fatty liver disease?","volume":"47","author":"Soifer","year":"2015","journal-title":"Hormone & Metabolic Research"},{"issue":"1","key":"10.1002\/14651858.CD011640.pub2-BIB0099|cit99","first-page":"9","article-title":"Silymarin in treatment of non-alcoholic steatohepatitis: a randomized clinical trial","volume":"5","author":"Solhi","year":"2014","journal-title":"Caspian Journal of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011640.pub2-BIB0100|cit100","first-page":"215","article-title":"Efficacy of sitagliptin combined with metformin in the initial treatment of type 2 diabetes with non-alcoholic fatty liver","volume":"23","author":"Song","year":"2014","journal-title":"Chinese Journal of New Drugs"},{"issue":"5","key":"10.1002\/14651858.CD011640.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S2213-8587(13)70170-0","article-title":"Inhibition of 11 beta-hsd1 with ro5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial","volume":"2","author":"Stefan","year":"2014","journal-title":"Lancet Diabetes & Endocrinology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD011640.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"S334","DOI":"10.1016\/S0168-8278(14)60953-3","article-title":"Effect of ursodeoxycholic acid or ursodeoxycholic acid combined with losartan for treatment of non-alcoholic steatohepatitis","volume":"60","author":"Stilidi","year":"2014","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0103|cit103","first-page":"A341","article-title":"Pioglitazone therapy improves insulin suppression of branched chain amino acids in patients with prediabetes or T2DM and NAFLD","volume":"64","author":"Sunny","year":"2015","journal-title":"Diabetes"},{"issue":"98","key":"10.1002\/14651858.CD011640.pub2-BIB0104|cit104","first-page":"164","article-title":"Efficacy of silymarin on treatment of nonalcoholic steatohepatitis","volume":"23","author":"Taghvaei","year":"2013","journal-title":"Journal of Mazandaran University of Medical Sciences"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0168-8278(11)60017-2","article-title":"Open-label prospective randomized 48 week clinical trial: rosiglitazone versus rosiglitazone and metformin (avandamet) versus rosiglitazone and losartan in the treatment of non-alcoholic steatohepatitis (NASH)","volume":"54","author":"Torres","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD011640.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/hep.24558","article-title":"Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial","volume":"54","author":"Torres","year":"2011","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"5","key":"10.1002\/14651858.CD011640.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2036.2004.01888.x","article-title":"Metformin in the treatment of patients with non-alcoholic steatohepatitis","volume":"19","author":"Uygun","year":"2004","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD011640.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1665-2681(19)31539-X","article-title":"Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial","volume":"10","author":"Wagner","year":"2011","journal-title":"Annals of Hepatology"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0109|cit109","first-page":"A620","article-title":"Sitagliptin decreases intrahepatic lipid accumulation in diabetic patients with NAFLD","volume":"64","author":"Wang","year":"2015","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0110|cit110","first-page":"793A","article-title":"Efficacy of low-dose pioglitazone for the treatment of NAFLD patients in japan","volume":"50","author":"Yaginuma","year":"2009","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0111|cit111","first-page":"A513","article-title":"Berberine vs. pioglitazone for treatment of nonalcoholic fatty liver disease and its associated impaired glucose metabolism","volume":"63","author":"Yan","year":"2014","journal-title":"Diabetes"},{"issue":"8","key":"10.1002\/14651858.CD011640.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"e0134172","DOI":"10.1371\/journal.pone.0134172","article-title":"Efficacy of berberine in patients with non-alcoholic fatty liver disease","volume":"10","author":"Yan","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1016\/S1590-8658(13)60468-5","article-title":"Metabolic effects of diet vs diet and silybin combined with phosphatidylcholine and vitamin E in overweight patients with non-alcoholic fatty liver disease","volume":"45","author":"Abenavoli","year":"2013","journal-title":"Digestive and Liver Disease"},{"issue":"4","key":"10.1002\/14651858.CD011640.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1586\/17474124.2015.1004312","article-title":"Effects of Mediterranean diet supplemented with silybin-vitamin E-phospholipid complex in overweight patients with non-alcoholic fatty liver disease","volume":"9","author":"Abenavoli","year":"2015","journal-title":"Expert Review of Gastroenterology & Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD011640.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1567-5688(07)71727-0","article-title":"Beyond glycated haemoglobin: effectiveness of rosiglitazone in type-2 diabetes with hypertension and non-alcoholic fatty liver. A randomized controlled one-year study","volume":"8","author":"Acquati","year":"2007","journal-title":"Atherosclerosis Supplements"},{"issue":"5","key":"10.1002\/14651858.CD011640.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"796","DOI":"10.5114\/aoms.2011.25554","article-title":"Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised attempt study","volume":"7","author":"Athyros","year":"2011","journal-title":"Archives of Medical Science"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/S1590-8658(12)60071-1","article-title":"Effect of statin therapy vs diet in hypercholesterolemic patients affected by nonalcoholic steatohepatitis (NASH)","volume":"44","author":"Carnelutti","year":"2012","journal-title":"Digestive and Liver Disease"},{"issue":"3","key":"10.1002\/14651858.CD011640.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/apt.13035","article-title":"Nash resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels","volume":"41","author":"Corey","year":"2015","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"3-4","key":"10.1002\/14651858.CD011640.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ajg.2015.09.001","article-title":"Essential phospholipids as a supportive adjunct in the management of patients with NAFLD","volume":"16","author":"Dajani","year":"2015","journal-title":"Arab Journal of Gastroenterology"},{"issue":"10","key":"10.1002\/14651858.CD011640.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.nutres.2014.09.005","article-title":"Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease","volume":"34","author":"Faghihzadeh","year":"2014","journal-title":"Nutrition Research"},{"issue":"2","key":"10.1002\/14651858.CD011640.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11655-010-0119-7","article-title":"Effect of xuezhikang capsule on serum tumor necrosis factor-alpha and interleukin-6 in patients with nonalcoholic fatty liver disease and hyperlipidemia","volume":"16","author":"Fan","year":"2010","journal-title":"Chinese Journal of Integrative Medicine"},{"issue":"9","key":"10.1002\/14651858.CD011640.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1590\/S0004-27302013000900005","article-title":"Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease","volume":"57","author":"Fan","year":"2013","journal-title":"Arquivos Brasileiros de Endocrinologia e Metabologia"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011640.pub2-BIB0123|cit123","first-page":"S164","article-title":"Improvement in hepatic metabolism is associated with reduced conversion to diabetes in IGT subjects treated with pioglitazone (act now study)","volume":"58","author":"Gastaldelli","year":"2015","journal-title":"Diabetologia"},{"issue":"4","key":"10.1002\/14651858.CD011640.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jacl.2012.01.009","article-title":"Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage)","volume":"6","author":"Han","year":"2012","journal-title":"Journal of Clinical Lipidology"},{"issue":"1","key":"10.1002\/14651858.CD011640.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40261-013-0136-3","article-title":"Randomized, vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose","volume":"34","author":"Han","year":"2014","journal-title":"Clinical Drug Investigation"},{"issue":"2","key":"10.1002\/14651858.CD011640.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2036.2008.03723.x","article-title":"Clinical trial: Insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis","volume":"28","author":"Idilman","year":"2008","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011640.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"S507","DOI":"10.1016\/S0168-8278(12)61297-5","article-title":"Vitamin E, pioglitazone and diet therapy for patients with nonalcoholic fatty liver disease (NAFLD): evaluation of treatment","volume":"56","author":"Jaafari Haidarlo","year":"2012","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"S268","DOI":"10.1016\/S0168-8278(15)30164-1","article-title":"Efficacy and safety of vitamin E for nonalcoholic steatohepatitis: Combined analysis of three controlled trials","volume":"62","author":"Kowdley","year":"2015","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0129|cit129","first-page":"264A","article-title":"Efficacy and safety of vitamin E in nonalcoholic steatohepatitis patients with and without diabetes: pooled analysis from the PIVENS and FLINT NIDDK NASH CRN trials","volume":"62","author":"Kowdley","year":"2015","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"22","key":"10.1002\/14651858.CD011640.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"7008","DOI":"10.3748\/wjg.v21.i22.7008","article-title":"Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis","volume":"21","author":"Li","year":"2015","journal-title":"World Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD011640.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"ofw062","DOI":"10.1093\/ofid\/ofw062","article-title":"Statin effects to reduce hepato steatosis as measured by computed tomography in patients with human immunodeficiency virus","volume":"3","author":"Lo","year":"2016","journal-title":"Open Forum Infectious Diseases"},{"issue":"8","key":"10.1002\/14651858.CD011640.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1007\/s00125-015-3628-2","article-title":"Impact of high dose n-3 polyunsaturated fatty acid treatment on measures of microvascular function and vibration perception in non-alcoholic fatty liver disease: Results from the randomised welcome trial","volume":"58","author":"McCormick","year":"2015","journal-title":"Diabetologia"},{"issue":"8","key":"10.1002\/14651858.CD011640.pub2-BIB0133|cit133","first-page":"515","article-title":"Polypill for prevention of cardiovascular disease in an urban Iranian population with special focus on nonalcoholic steatohepatitis: a pragmatic randomized controlled trial within a cohort (polyiran - liver) - study protocol","volume":"18","author":"Merat","year":"2015","journal-title":"Archives of Iranian Medicine"},{"issue":"4","key":"10.1002\/14651858.CD011640.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/ijcp.12790","article-title":"Efficacy and safety of ursodeoxycholic acid composite on fatigued patients with elevated liver function and\/or fatty liver: a multi-centre, randomised, double-blinded, placebo-controlled trial","volume":"70","author":"Oh","year":"2016","journal-title":"International Journal of Clinical Practice"},{"issue":"4","key":"10.1002\/14651858.CD011640.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/hep.27289","article-title":"Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study","volume":"60","author":"Scorletti","year":"2014","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"6","key":"10.1002\/14651858.CD011640.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jhep.2015.07.036","article-title":"Treating liver fat and serum triglyceride levels in NAFLD, effects of pnpla3 and tm6sf2 genotypes: results from the Welcome trial","volume":"63","author":"Scorletti","year":"2015","journal-title":"Journal of Hepatology"},{"issue":"10","key":"10.1002\/14651858.CD011640.pub2-BIB0137|cit137","first-page":"1417","article-title":"Effect of vitamin E and metformin on fatty liver disease in obese children- randomized clinical trial","volume":"43","author":"Shiasi Arani","year":"2014","journal-title":"Iranian Journal of Public Health"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0138|cit138","first-page":"S500","article-title":"A comparative study with metformin and pioglitazone versus metformin alone in nonalcoholic fatty liver disease in newly detected glucose intolerant patients","volume":"55","author":"Sultana","year":"2012","journal-title":"Diabetologia"},{"issue":"100","key":"10.1002\/14651858.CD011640.pub2-BIB0139|cit139","first-page":"36","article-title":"The effect of chlorella vulgaris vs. Artichoke on patients with non-alcoholic fatty liver disease (NAFLD): a randomized clinical trial","volume":"23","author":"Talebi Pour","year":"2015","journal-title":"Journal of Zanjan University of Medical Sciences and Health Services"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0140|cit140","first-page":"162","article-title":"A randomized, unblinded pilot trial of essential phospholipids in Chinese subjects with nonalcoholic fatty liver disease (NASH)","volume":"26","author":"Tan","year":"2011","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"7","key":"10.1002\/14651858.CD011640.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1872-034X.2009.00507.x","article-title":"Treatment of nonalcoholic steatohepatitis with colestimide","volume":"39","author":"Taniai","year":"2009","journal-title":"Hepatology Research"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0142|cit142","first-page":"A595","article-title":"Alogliptin decreases liver fat content in patients with IGT or type Q2 DM: comparing alogliptin and voglibose","volume":"60","author":"Tsuchiya","year":"2011","journal-title":"Diabetes"},{"issue":"4","key":"10.1002\/14651858.CD011640.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"S1036","DOI":"10.1016\/S0016-5085(16)33501-6","article-title":"Losartan improves hepatic inflammation in children with non-alcoholic fatty liver disease","volume":"150","author":"Vos","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0144|cit144","first-page":"186","article-title":"Clinical effect of metformin combined with reduced glutathione in non-alcoholic fatty liver disease","volume":"28","author":"Wang","year":"2013","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD011640.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.cgh.2006.02.004","article-title":"A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease","volume":"4","author":"Zelber-Sagi","year":"2006","journal-title":"Clinical Gastroenterology & Hepatology"},{"issue":"4 Supl 1","key":"10.1002\/14651858.CD011640.pub2-BIB0146|cit146","first-page":"237a","article-title":"Randomized placebo-controlled trial of orlistat for the treatment of patients with non alcoholic fatty liver disease (NAFLD)","volume":"40","author":"Zelber-Sagi","year":"2004","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"6","key":"10.1002\/14651858.CD011640.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"1125-49, ix","DOI":"10.1016\/j.mcna.2007.06.001","article-title":"Nonalcoholic fatty liver disease as a complication of insulin resistance","volume":"91","author":"Abdelmalek","year":"2007","journal-title":"Medical Clinics of North America"},{"issue":"8","key":"10.1002\/14651858.CD011640.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1586\/17474124.2013.842893","article-title":"Milk thistle to treat non-alcoholic fatty liver disease: dream or reality?","volume":"7","author":"Abenavoli","year":"2013","journal-title":"Expert Review of Gastroenterology & Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD011640.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","article-title":"The natural history of nonalcoholic fatty liver disease: a population-based cohort study","volume":"129","author":"Adams","year":"2005","journal-title":"Gastroenterology"},{"issue":"17-18","key":"10.1002\/14651858.CD011640.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.drudis.2012.05.012","article-title":"Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis","volume":"17","author":"Adorini","year":"2012","journal-title":"Drug Discovery Today"},{"issue":"16","key":"10.1002\/14651858.CD011640.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD011640.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD011640.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jhep.2012.04.041","article-title":"S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility","volume":"57","author":"Anstee","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD011640.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/jgh.13264","article-title":"Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis","volume":"31","author":"Ballestri","year":"2016","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD011640.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.20734","article-title":"Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study","volume":"42","author":"Bedogni","year":"2005","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"5","key":"10.1002\/14651858.CD011640.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/hep.21827","article-title":"Incidence and natural course of fatty liver in the general population: the Dionysos study","volume":"46","author":"Bedogni","year":"2007","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"3","key":"10.1002\/14651858.CD011640.pub2-BIB0157|cit157","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011646.pub2","article-title":"Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease): a network meta-analysis","author":"Buzzetti","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD011640.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/jrsm.57","article-title":"Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions","volume":"3","author":"Chaimani","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"10","key":"10.1002\/14651858.CD011640.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PloS One"},{"issue":"6","key":"10.1002\/14651858.CD011640.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association","volume":"55","author":"Chalasani","year":"2012","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD011640.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"Spirit 2013 statement: Defining standard protocol items for clinical trials","volume":"158","author":"Chan","year":"2013","journal-title":"Annals of Internal Medicine"},{"issue":"7","key":"10.1002\/14651858.CD011640.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/j.1440-1746.2009.05831.x","article-title":"Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population","volume":"24","author":"Dassanayake","year":"2009","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD011640.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"e63509","DOI":"10.1371\/journal.pone.0063509","article-title":"Efficacy of new generation antidepressants: differences seem illusory","volume":"8","author":"Re","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1002\/14651858.CD011640.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/sim.4780060325","article-title":"Methods for combining randomized clinical trials: strengths and limitations","volume":"6","author":"DeMets","year":"1987","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD011640.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"7-8","key":"10.1002\/14651858.CD011640.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0167|cit167","unstructured":"Dias S Welton NJ Sutton AJ Ades AE NICE DSU Technical Support Document 1: introduction to evidence synthesis for decision making, April 2011 (last updated April 2012) www.nicedsu.org.uk\/TSD1%20Introduction.final.08.05.12.pdf"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0168|cit168","unstructured":"Dias S Sutton AJ Welton NJ Ades AE NICE DSU Technical Support Document 3: heterogeneity: subgroups, meta-regression, bias and bias-adjustment, September 2011 (last updated April 2012) www.nicedsu.org.uk\/TSD3%20Heterogeneity.final%20report.08.05.12.pdf"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0169|cit169","unstructured":"Dias S Welton NJ Sutton AJ Caldwell DM Lu G Ades AE NICE DSU Technical Support Document 4: inconsistency in networks of evidence based on randomised controlled trials, May 2011 (last updated April 2014) www.nicedsu.org.uk\/TSD4%20Inconsistency.final.15April2014.pdf"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0170|cit170","unstructured":"Dias S Welton NJ Sutton AJ Ades AE NICE DSU Technical Support Document 2: a generalised linear modelling framework for pair wise and network meta-analysis of randomised controlled trials, August 2011 (last updated April 2014) www.nicedsu.org.uk\/TSD2%20General%20meta%20analysis%20corrected%2015April2014.pdf"},{"issue":"3","key":"10.1002\/14651858.CD011640.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","article-title":"Statin use and non-alcoholic steatohepatitis in at risk individuals","volume":"63","author":"Dongiovanni","year":"2015","journal-title":"Journal of Hepatology"},{"issue":"7109","key":"10.1002\/14651858.CD011640.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0173|cit173","unstructured":"EuroQol About EQ-5D, 2014 www.euroqol.org\/about-eq-5d.html"},{"issue":"17","key":"10.1002\/14651858.CD011640.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.3748\/wjg.v20.i17.4987","article-title":"NAFLD prevalence differs among Hispanic subgroups: the multi-ethnic study of atherosclerosis","volume":"20","author":"Fleischman","year":"2014","journal-title":"World Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD011640.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jhep.2007.01.003","article-title":"Hepatology may have problems with putative surrogate outcome measures","volume":"46","author":"Gluud","year":"2007","journal-title":"Journal of hepatology"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0176|cit176","unstructured":"Gluud C Nikolova D Klingenberg SL Cochrane Hepato-Biliary Group About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2016, Issue 10. Art. No.: LIVER"},{"issue":"6","key":"10.1002\/14651858.CD011640.pub2-BIB0177|cit177","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000493.pub2","article-title":"Interventions for treating cholestasis in pregnancy","author":"Gurung","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD011640.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD011640.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/hep.24452","article-title":"Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis","volume":"54","author":"Hernaez","year":"2011","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0180|cit180","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"2","key":"10.1002\/14651858.CD011640.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: Concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0182|cit182","volume-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice CFR & ICH Guidelines","volume":"1","author":"International Conference on Harmonisation Expert Working Group","year":"1997"},{"issue":"1","key":"10.1002\/14651858.CD011640.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/1471-2288-14-120","article-title":"Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods","volume":"14","author":"Jakobsen","year":"2014","journal-title":"BMC Medical Research Methodology"},{"issue":"9","key":"10.1002\/14651858.CD011640.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.nut.2014.01.016","article-title":"Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH, and CHC: results from a meta-analysis","volume":"30","author":"Ji","year":"2014","journal-title":"Nutrition"},{"issue":"11","key":"10.1002\/14651858.CD011640.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Annals of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD011640.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.jhep.2012.07.028","article-title":"Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study","volume":"57","author":"Koehler","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD011640.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/aje\/kws448","article-title":"Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994","volume":"178","author":"Lazo","year":"2013","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1476-511X-10-49","article-title":"Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease","volume":"10","author":"Li","year":"2011","journal-title":"Lipids in Health & Disease"},{"issue":"1","key":"10.1002\/14651858.CD011640.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3892\/br.2012.18","article-title":"Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"1","author":"Li","year":"2013","journal-title":"Biomedical Reports"},{"issue":"1","key":"10.1002\/14651858.CD011640.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/jgh.12428","article-title":"Prevalence of nonalcoholic fatty liver disease in mainland of China: a meta-analysis of published studies","volume":"29","author":"Li","year":"2014","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD011640.pub2-BIB0191|cit191","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004996.pub3","article-title":"Antioxidant supplements for non-alcoholic fatty liver disease and\/or steatohepatitis","author":"Lirussi","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD011640.pub2-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.dld.2015.08.004","article-title":"Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups","volume":"47","author":"Lonardo","year":"2015","journal-title":"Digestive and Liver Disease"},{"issue":"474","key":"10.1002\/14651858.CD011640.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1198\/016214505000001302","article-title":"Assessing evidence inconsistency in mixed treatment comparisons","volume":"101","author":"Lu","year":"2006","journal-title":"Journal of the American Statistical Association"},{"issue":"2","key":"10.1002\/14651858.CD011640.pub2-BIB0194|cit194","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000033.pub3","article-title":"Industry sponsorship and research outcome","author":"Lundh","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD011640.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/sim.698","article-title":"A comparison of methods to detect publication bias in meta-analysis","volume":"20","author":"Macaskill","year":"2001","journal-title":"Statistics in Medicine"},{"issue":"6","key":"10.1002\/14651858.CD011640.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.jhep.2011.03.016","article-title":"The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis","volume":"55","author":"Mahady","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"12","key":"10.1002\/14651858.CD011640.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1001\/2012.jama.11228","article-title":"How to use an article reporting a multiple treatment comparison meta-analysis","volume":"308","author":"Mills","year":"2012","journal-title":"JAMA"},{"issue":"9128","key":"10.1002\/14651858.CD011640.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0199|cit199","unstructured":"National Center for Biotechnology Information (NCBI) Fatty liver, 2014 www.ncbi.nlm.nih.gov\/mesh\/68005234"},{"issue":"5","key":"10.1002\/14651858.CD011640.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/ije\/21.5.837","article-title":"Intention-to-treat analysis: implications for quantitative and qualitative research","volume":"21","author":"Newell","year":"1992","journal-title":"International Journal of Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD011640.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00535-014-0948-9","article-title":"Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011-2012","volume":"50","author":"Nishioji","year":"2015","journal-title":"Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD011640.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jhep.2008.06.018","article-title":"Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease","volume":"49","author":"Ong","year":"2008","journal-title":"Journal of Hepatology"},{"issue":"9","key":"10.1002\/14651858.CD011640.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3109\/00365521.2014.934911","article-title":"Increased risk of cirrhosis and hepatocellular cancer during long-term follow-up of patients with biopsy-proven NAFLD","volume":"49","author":"Onnerhag","year":"2014","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0204|cit204","unstructured":"Members of OpenBUGS Project Management Group OpenBUGS 2014"},{"issue":"1","key":"10.1002\/14651858.CD011640.pub2-BIB0205|cit205","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005160.pub2","article-title":"Bile acids for non-alcoholic fatty liver disease and\/or steatohepatitis","author":"Orlando","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1 Pt 1","key":"10.1002\/14651858.CD011640.pub2-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1440-1746.2005.04086.x","article-title":"Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults","volume":"21","author":"Park","year":"2006","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"12","key":"10.1002\/14651858.CD011640.pub2-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4254\/wjh.v4.i12.327","article-title":"Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment","volume":"4","author":"Paschos","year":"2012","journal-title":"World Journal of Hepatology"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0208|cit208","first-page":"g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0209|cit209","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"12","key":"10.1002\/14651858.CD011640.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1136\/jcp.2006.044891","article-title":"A growing burden: the pathogenesis, investigation and management of non-alcoholic fatty liver disease","volume":"60","author":"Riley","year":"2007","journal-title":"Journal of Clinical Pathology"},{"issue":"22","key":"10.1002\/14651858.CD011640.pub2-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: a systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD011640.pub2-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1017\/S0266462303000552","article-title":"Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches","volume":"19","author":"Royle","year":"2003","journal-title":"International Journal of Technology Assessment in Health Care"},{"issue":"3","key":"10.1002\/14651858.CD011640.pub2-BIB0213|cit213","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011343.pub2","article-title":"Pharmacological interventions for primary sclerosing cholangitis: an attempted network meta-analysis","author":"Saffioti","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD011640.pub2-BIB0214|cit214","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011648.pub2","article-title":"Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis","author":"Saffioti","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD011640.pub2-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD011640.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1037","article-title":"Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool","volume":"3","author":"Salanti","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"8","key":"10.1002\/14651858.CD011640.pub2-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1053\/j.gastro.2016.02.044","article-title":"Regulatory science and drug approval for alcoholic and nonalcoholic steatohepatitis","volume":"150","author":"Sanyal","year":"2016","journal-title":"Gastroenterology"},{"issue":"35","key":"10.1002\/14651858.CD011640.pub2-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16350","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomized controlled trials: combined analysis of meta-epidemiological studies","volume":"16","author":"Savovi\u0107","year":"2012","journal-title":"Health Technology Assessment"},{"issue":"6","key":"10.1002\/14651858.CD011640.pub2-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"429","DOI":"10.7326\/0003-4819-157-6-201209180-00537","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomized controlled trials","volume":"157","author":"Savovi\u0107","year":"2012","journal-title":"Annals of Internal Medicine"},{"issue":"32","key":"10.1002\/14651858.CD011640.pub2-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"e4529","DOI":"10.1097\/MD.0000000000004529","article-title":"Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): a prisma-compliant systematic review and network meta-analysis","volume":"95","author":"Sawangjit","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1002\/14651858.CD011640.pub2-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD011640.pub2-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"e1000251","DOI":"10.1371\/journal.pmed.1000251","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"7","author":"Schulz","year":"2010","journal-title":"PLoS Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011640.pub2-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.2517-6161.1993.tb01921.x","article-title":"Bayesian interval estimates which are also confidence intervals","volume":"55","author":"Severini","year":"1993","journal-title":"Journal of the Royal Statistical Society. Series B (Methodological)"},{"issue":"9","key":"10.1002\/14651858.CD011640.pub2-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/apt.12944","article-title":"Association between aspirin use and the prevalence of nonalcoholic fatty liver disease: a cross-sectional study from the Third National Health and Nutrition Examination Survey","volume":"40","author":"Shen","year":"2014","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD011640.pub2-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/hep.27999","article-title":"Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: a systematic review and network meta-analysis","volume":"62","author":"Singh","year":"2015","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"2","key":"10.1002\/14651858.CD011640.pub2-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/hep.23314","article-title":"Decreased survival of subjects with elevated liver function tests during a 28-year follow-up","volume":"51","author":"Soderberg","year":"2010","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0227|cit227","unstructured":"StataCorp LP Stata\/SE 14.2 for Windows[64-bit x86-64] 2017"},{"issue":"1","key":"10.1002\/14651858.CD011640.pub2-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jhep.2011.06.010","article-title":"Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review","volume":"56","author":"Thoma","year":"2012","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0229|cit229","unstructured":"Thorlund K Engstr\u00f8m J Wetterslev J Brok J Imberger G Gluud C User manual for Trial Sequential Analysis (TSA) ctu.dk\/tsa\/files\/tsa_manual.pdf"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/2046-4053-1-41","article-title":"Sample size and power considerations in network meta-analysis","volume":"1","author":"Thorlund","year":"2012","journal-title":"Systematic Reviews"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0231|cit231","unstructured":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen TSA version 0.9 2011"},{"issue":"3","key":"10.1002\/14651858.CD011640.pub2-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/ije\/dys041","article-title":"Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews","volume":"41","author":"Turner","year":"2012","journal-title":"International Journal of Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD011640.pub2-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/jrsm.1054","article-title":"Automating network meta-analysis","volume":"3","author":"Valkenhoef","year":"2012","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0234|cit234","unstructured":"Ware JE SF-36 health survey update, 2014 www.sf-36.org\/tools\/sf36.shtml"},{"issue":"1","key":"10.1002\/14651858.CD011640.pub2-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD011640.pub2-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12874-017-0315-7","article-title":"Trial Sequential Analysis in systematic reviews with meta-analysis","volume":"17","author":"Wetterslev","year":"2017","journal-title":"BMC Medical Research Methodology"},{"issue":"7644","key":"10.1002\/14651858.CD011640.pub2-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD011640.pub2-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1471-230X-13-140","article-title":"The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review","volume":"13","author":"Xiang","year":"2013","journal-title":"BMC Gastroenterology"},{"issue":"16","key":"10.1002\/14651858.CD011640.pub2-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"21753","DOI":"10.18632\/oncotarget.7832","article-title":"Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma","volume":"7","author":"Zhou","year":"2016","journal-title":"Oncotarget"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD011640.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T16:52:07Z","timestamp":1683219127000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011640.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Hepato-Biliary Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,3,30]]},"references-count":239,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011640.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,30]]}}}